Regeneron Pharmaceuticals (NQ: REGN )
759.76 +0.51 (+0.07%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Press Releases about Regeneron Pharmaceuticals
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
March 14, 2023
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
March 07, 2023
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
February 24, 2023
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone
Regeneron Announces Investor Conference Presentations
January 31, 2023
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
November 17, 2022
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range
Via Spotlight Growth
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc.
May 31, 2022
San Diego, CA -- (SBWIRE) -- 05/31/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Regeneron Pharmaceuticals, Inc.
NASDAQ: REGN Shareholder Notice: Investigation over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc.
April 15, 2022
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- Regeneron Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following